

Exploiting Adamantane as a Versatile Organic Tecton: Multicomponent Catalytic Cascade Reactions.

Ronald Grigg,^a* Elghareeb E. Elboray,^{a,b} Moustafa F. Aly^b and Hussien H. Abbas-Temirek^b

^a School of Chemistry, University of Leeds, Leeds, UK, LS6 9JT.

^b Department of Chemistry, Faculty of Science at Qena, South Valley University, Qena, Egypt.

r.grigg@leeds.ac.uk

Table of contents

1. General technical data.....	2
2. General Procedure A: N-propargylation.....	2
3. General Procedure B: allene formation.....	4
4. General Procedure C: Pd catalysed 3-component cascades.....	5
5. General Procedure D: Pd catalysed 9-component cascades.....	13
6. References.....	24
7. HRMS of 9-component cascade products.....	25

General technical data.

Thin layer chromatography (TLC) was carried out on a pre-coated aluminium plates with silica gel 60 F254 (Merck), and was visualised using ultraviolet light and/or aqueous KMnO_4/I_2 . Flash column chromatography employed silica gel 60 (Merck, 230-400mesh). Melting points were determined on a Reichert hot-stage microscope and are uncorrected. Optical rotations were calculated using Polartronic H 532 (Schmidt + Haensch) instrument. Infrared spectra were recorded using a Perkin-Elmer Spectrum FT-IR spectrometer either as a thin film on sodium chloride discs or as a solid using golden gate apparatus. Proton nuclear magnetic resonance spectra were recorded at 500 and 300MHz on a Bruker DRX500 and DPX300 instruments, respectively. Chemical shifts (δ) are reported in parts per million relative to tetramethylsilane ($\delta = 0.00$) and coupling constants are given in hertz (Hz). The following abbreviations are used: s = singlet, br = broad, d = doublet, dd = doublet of doublets, ddd = doublet of double doublets, dt = doublet of triplets, m = multiplet, t = triplet, td = triplet of doublets. ^{13}C -NMR spectra were recorded at 75 MHz on a Bruker DPX300 instrument and chemical shifts are reported in parts per million (ppm). Mass spectral data were determined at 70 eV on a Micromass ZMD 2000 electrospray (ES) machine. Accurate masses were obtained using a Bruker Daltonics micrOTOF spectrometer. The m/z data mentioned in case of 9-component cascades are the result of two runs using the auto sampler technique and by injecting the sample directly to the machine using a syringe pump.


^1H -NMR peak assignments are mainly based on DEPT135, COSY, HMQC and HMBC spectral data.

All compounds were named according to the IUPAC system using the ACD/ILAB (ACD/IUPAC v.12.0 programme) web service (<http://www.acdlabs.com>).

General Procedure A: N-propargylation.


Propargyl bromide (80% solution in toluene, 2 equiv.) was added to a solution of the NH-heterocycle (1 equiv.) and K_2CO_3 in dry acetone and the mixture was stirred at room temperature for 16h. The mixture was filtered, the solvent removed under reduced pressure and the residue dissolved in CHCl_3 (20 mL). The organic layer was washed with water (2×10 mL), dried over anhydrous MgSO_4 , filtered and the filtrate evaporated under *vacuo* to afford the product.

2',3',5'-Tri-*O*-acetyl-3-prop-2-yn-1-yluridine.¹



Prepared by general procedure A from 2',3',5'-tri-*O*-acetyluridine. Flash column chromatography eluting with 7:3 v/v EtOAc/n-hexane afforded the product as a colourless gum (93%), $[\alpha]_D +17.1$ (*c*, 35 mg/10 mL CH₂Cl₂); δ_H (500 MHz, CDCl₃); 7.41 (1H, d, *J* 8.2, pyrimidinyl 6-H), 6.02 (1H, d, *J* 4.7, ribosyl 1-H), 5.86 (1H, d, *J* 8.2, pyrimidinyl 5-H), 5.38 (1H, dd, *J* 5.9 and 4.7, ribosyl 2-H), 5.35-5.31 (1H, m, ribosyl 3-H), 4.71 (1H, dd, *J* 16.4 and 2.1, NCH_AC≡), 4.65 (1H, dd, *J* 16.4 and 2.6, NCH_BC≡), 4.36 (3H, br s, ribosyl 4-H and 5-CH₂), 2.18 (1H, dd, *J* 2.6 and 2.1, ≡CH), 2.14 (3H, s, OCOMe), 2.12 (3H, s, OCOMe), 2.11 (3H, s, OCOMe); δ_c (75 MHz, CDCl₃); 170.5, 170.1, 170.0, 163.3, 161.5, 150.5, 138.2, 103.1, 89.2, 80.1, 73.3, 71.3, 70.2, 63.2, 30.7, 21.2, 20.9, 20.8; ν_{max}/cm^{-1} (film); 2396, 2125, 1747, 1711, 1670, 1456, 1376, 1233; *m/z* (ES, %) 409 (MH⁺, 65).

3',5'-Di-*O*-acetyl-3-prop-2-yn-1-ylthymidine.




Prepared by general procedure A from 3',5'-di-*O*-acetylthymidine. Flash column chromatography eluting with 2:1 v/v EtOAc/n-hexane gave the product as a colourless gum (90%), $[\alpha]_D -3.2$ (*c*, 10 mg/1 mL CH₂Cl₂); (Found: C, 55.90; H, 5.80; N, 7.45; C₁₇H₂₀N₂O₇ requires C, 56.04; H, 5.53; N, 7.69%); δ_H (500 MHz, CDCl₃); 7.29 (1H, br s, pyrimidinyl 6-H), 6.37 (1H, dd, *J* 9.1 and 5.9, deoxyribosyl 1-H), 5.22 (1H, dt, *J* 6.6 and 2.1, deoxyribosyl 3-H), 4.72 (2H, d, *J* 2.6, NCH₂C≡), 4.38-4.34 (2H, m, deoxyribosyl 5-CH₂), 4.26 (1H, m, deoxyribosyl 4-H), 2.50 (1H, ddd, *J* 14.3, 5.9 and 2.1, deoxyribosyl 2-H_A), 2.18-2.15 (1H, m, deoxyribosyl 2-H_B), 2.16 (1H, m, ≡CH), 2.13 (3H, s, OCOMe), 2.11 (3H, s, OCOMe), 1.98 (3H, s, pyrimidinyl 5-Me); δ_c (75 MHz, CDCl₃); 170.7, 170.4, 162.3, 150.2, 147.5, 145.6,

132.9, 85.5, 82.0, 74.0, 70.6, 63.8, 37.6, 30.4, 20.9, 20.8, 13.3; $\nu_{\text{max}}/\text{cm}^{-1}$ (film); 3272, 2955, 1743, 1707, 1673, 1651, 1466, 1369, 1333, 1234; m/z (ES, %) 365 (MH^+ , 100).

General Procedure B: Allene formation.²


A mixture of alkyne (1 equiv.), dicyclohexylamine (1.8 equiv.), paraformaldehyde (2.5 equiv.) and CuI (0.5 equiv.) in dry dioxane was refluxed for 3h. The reaction mixture was cooled and the solvent removed under reduced pressure. The residue was dissolved in CHCl_3 and the organic layer washed with (10%) NH_4OH three times then with water, dried over anhydrous MgSO_4 , filtered and the filtrate evaporated under *vacuo* to give the crude allene which was purified by flash column chromatography.

1-(Buta-2,3-dien-1-yl)-3,7-dimethyl-3,7-dihydro-1*H*-purine-2,6-dione (4a).³



Prepared by general procedure B from 3,7-dimethyl-1-(prop-2-yn-1-yl)-3,7-dihydro-1*H*-purine-2,6-dione.^{4,5} Flash column chromatography eluting with EtOAc gave **4a** as a colourless fine needles (83%), mp. 128-130 °C; (Found: C, 56.70; H, 5.10; N, 24.15; $\text{C}_{11}\text{H}_{12}\text{N}_4\text{O}_2$ requires C, 56.89; H, 5.21; N, 24.12%); δ_{H} (300 MHz, CDCl_3); 7.53 (1H, s, purine 8-H), 5.36-5.27 (1H, m, $\text{CH}_2\text{CH}=$), 4.83-4.78 (2H, m, $\text{NCH}_2\text{CH}=$), 4.65-4.61 (2H, m, = CH_2), 4.00 (3H, s, NMe), 3.58 (3H, s, NMe); δ_{c} (75 MHz, CDCl_3); 208.8, 154.9, 151.2, 148.8, 141.5, 107.6, 86.3, 77.0, 39.5, 33.6, 29.7; $\nu_{\text{max}}/\text{cm}^{-1}$ (film); 3115, 2950, 1701, 1654, 1598, 1477, 1332; m/z (ES, %) 233 (MH^+ , 100).


2',3',5'-Tri-*O*-acetyl-3-buta-2,3-dien-1-yluridine (4b).



Prepared by general procedure B from 2',3',5'-tri-*O*-acetyl-3-prop-2-yn-1-yluridine. Flash column chromatography eluting with 2:1 v/v EtOAc/*n*-hexane gave **4b** as a colourless gum

(80%), $[\alpha]_D + 30.6$ (c , 4.2 mg/1 mL CH_2Cl_2); (Found: C, 53.85; H, 5.00; N, 6.45; $\text{C}_{19}\text{H}_{22}\text{N}_2\text{O}_9$ requires C, 54.03; H, 5.25; N, 6.63%); δ_{H} (500 MHz, CDCl_3); 7.37 (1H, d, J 8.1, pyrimidinyl 6-H), 6.01 (1H, d, J 4.3, ribosyl 1-H), 5.82 (1H, d, J 8.1, pyrimidinyl 5-H), 5.38 (1H, dd, J 5.9 and 4.3, ribosyl 2-H), 5.35-5.31 (1H, m, ribosyl 3-H), 5.29-5.23 (1H, m, $\text{CH}_2\text{CH} =$), 4.83-4.80 (2H, m, $\text{NCH}_2\text{CH} =$), 4.55-4.51 (2H, m, = CH_2), 4.36 (3H, br s, ribosyl 4-H and 5- CH_2), 2.15 (3H, s, OCOMe), 2.12 (3H, s, OCOMe), 2.11 (3H, s, OCOMe); δ_{c} (75 MHz, CDCl_3); 209.2, 170.6, 170.5, 169.9, 162.1, 150.8, 137.8, 103.1, 89.2, 86.0, 80.0, 77.6, 73.3, 71.3, 63.3, 39.6, 21.4, 21.1, 20.8; $\nu_{\text{max}}/\text{cm}^{-1}$ (film); 2107, 1960, 1746, 1666, 1457, 1423, 1388, 1229; m/z (ES, %) 423 (MH^+ , 100).

3',5'-Di-O-acetyl-3-buta-2,3-dien-1-ylthymidine (4c).




Prepared by general procedure B from 3',5'-di-O-acetyl-3-prop-2-yn-1-ylthymidine. Flash column chromatography eluting with 1:1 v/v EtOAc/n-hexane gave **4c** as a colourless gum (75%), $[\alpha]_D + 17.0$ (c , 10 mg/1 mL CH_2Cl_2); (Found: C, 57.05; H, 5.85; N, 7.40; $\text{C}_{18}\text{H}_{22}\text{N}_2\text{O}_7$ requires C, 57.14; H, 5.86; N, 7.40%); δ_{H} (500 MHz, CDCl_3); 7.27 (1H, br s, pyrimidinyl 6-H), 6.35 (1H, dd, J 8.6 and 5.6, deoxyribosyl 1-H), 5.27 (1H, tt, J 12.8 1nd 6.4, $\text{CH}_2\text{CH} =$), 5.23-5.21 (1H, m, deoxyribosyl 3-H), 4.80 (2H, dt, J 6.4 and 3.0, $\text{NCH}_2\text{CH} =$), 4.56 (2H, dt, J 6.4 and 3.0, = CH_2), 4.36 (2H, d, J 3.9, deoxyribosyl 5- CH_2), 4.25 (1H, dt, J 5.9 and 3.9, deoxyribosyl 4-H), 2.49 (1H, ddd, J 14.1, 5.6 and 2.0, deoxyribosyl 2-H_A), 2.18-2.15 (1H, m, deoxyribosyl 2-H_B), 2.13 (3H, s, OCOMe), 2.11 (3H, s, OCOMe), 1.96 (3H, s, pyrimidinyl 5-Me); δ_{c} (75 MHz, CDCl_3); 209.5, 170.8, 170.5, 163.1, 150.9, 132.9, 111.0, 86.1, 85.8, 82.4, 77.3, 74.5, 64.2, 39.9, 38.0, 21.4, 21.2, 13.8; $\nu_{\text{max}}/\text{cm}^{-1}$ (film); 2954, 1957, 1744, 1703, 1671, 1647, 1466, 1367, 1232; m/z (ES, %) 379 (MH^+ , 100).

General Procedure C: Pd catalysed 3-component cascades.

A mixture of substituted allene **4** (1 equiv.), aryl/heteroaryl iodide **5** (1.2 equiv.), 1-amino adamantane **1** (1.2 equiv.), $\text{Pd}_2(\text{dba})_3$ (2.5 mol%), TFP (tri-(2-furyl)phosphine) (10 mol%) and K_2CO_3 (3 equiv.) in MeCN was stirred and heated at 80 °C (oil bath temperature).

The mixture was cooled, filtered and the inorganic precipitate washed with MeCN. The filtrate was evaporated under reduced pressure and the resulting residue dissolved in CHCl₃ and washed with saturated NH₄Cl and then with saturated NaCl. The organic layer was dried with anhydrous MgSO₄, filtered, and the filtrate evaporated under reduced pressure. The residue was purified by flash chromatography.

1-[(2Z)-4-(Adamantan-1-ylamino)-3-(pyridin-3-yl)but-2-en-1-yl]-3,7-dimethyl-3,7-dihydro-1*H*-purine-2,6-dione (6a**).**




Prepared by general procedure C from **4a** and heating for 5h. Gradient elution chromatography with EtOAc and then 10:1 v/v EtOAc/MeOH gave the product **6a** (78%) as a colourless froth, mp 91–93°C; δ_H (300 MHz, CDCl₃): 8.77 (1H, d, *J* 1.5, pyridyl-H), 8.45 (1H, dd, *J* 4.9 and 1.5, pyridyl-H), 7.87 (1H, dt, *J* 8.0 and 1.5, pyridyl-H), 7.55 (1H, s, purine-H), 7.21 (1H, ddd, *J* 8.0, 4.9 and 0.5, pyridinyl-H), 5.90 (1H, t, *J* 7.1, NCH₂CH=), 4.90 (2H, d, *J* 7.1, NCH₂CH=), 4.00 (3H, s, NMe), 3.82 (2H, s, =CCH₂N), 3.59 (3H, s, NMe), 2.10 (3H, br s, 3 × adamantyl-CH), 1.78 (6H, d, *J* 2.3, 3 × adamantyl-CH₂), 1.67 (6H, br s, 3 × adamantyl-CH₂); δ_C (75 MHz, CDCl₃): 155.4, 151.7, 149.3, 148.7, 148.1, 142.0, 139.6, 137.5, 134.1, 126.1, 123.4, 108.0, 51.4, 42.9, 39.9, 39.6, 37.2, 34.0, 30.2, 30.0; ν_{max}/cm⁻¹ (film): 2906, 2848, 1704, 1661, 1550, 1455, 1358, 1310, 1234; *m/z* (ESI⁺) 461.3 (100%, MH⁺); (Found MH⁺, 461.2675. C₂₆H₃₃N₆O₂ requires MH, 461.2660).

NOE data (CDCl₃) for **6a**:


Irradiated proton	% Enhancement				
	1-H	2-H	4-H	Pyridyl-H	adamantyl-CH ₂ (δ 1.74)
1-H		6.8	3.6	-	-
2-H	3.2		-	8.4 (δ 8.77) 6.1 (δ 7.87)	-
4-H	4.3	-		4.4 (δ 8.77) 3.6 (δ 7.87)	6.8

1-[*(2E*)-4-(Adamantan-1-ylamino)-3-(2-thienyl)but-2-en-1-yl]-3,7-dimethyl-3,7-dihydro-1*H*-purine-2,6-dione (6b**).**



Prepared by general procedure C from **4a** and heating for 2h. Flash chromatography eluting with EtOAc gave the product **6b** (69%) as a colourless froth, mp 155–157°C; δ_{H} (300 MHz, CDCl₃): 7.50 (1H, s, purine-H), 7.17 (1H, dd, *J* 3.6 and 1.0, thienyl-H), 7.11 (1H, dd, *J* 5.1 and 1.0, thienyl-H), 6.93 (1H, dd, *J* 5.1 and 3.6, thienyl-H), 5.97 (1H, t, *J* 7.2, NCH₂CH=), 4.85 (2H, d, *J* 7.2, NCH₂CH=), 3.98 (3H, s, NMe), 3.81 (2H, s, =CCH₂N), 3.57 (3H, s, NMe), 2.11 (3H, br s, 3 × adamantyl-CH), 1.80 (6H, d, *J* 2.6, 3 × adamantyl-CH₂), 1.68 (6H, d, *J* 2.1, 3 × adamantyl-CH₂); δ_{c} (75 MHz, CDCl₃): 154.9, 151.2, 148.7, 145.3, 141.5, 136.4, 127.2, 124.1, 123.8, 122.1, 107.5, 50.9, 42.5, 39.7, 39.2, 36.8, 33.5, 29.7, 29.4; $\nu_{\text{max}}/\text{cm}^{-1}$ (film): 2903, 2846, 1702, 1660, 1549, 1454, 1361, 1310, 1233; *m/z* (ESI⁺) 466.2 (100%, MH⁺); (Found MH⁺, 466.2289. C₂₅H₃₂N₅O₂³²S requires MH, 466.2271).


1-{(2Z)-4-(Adamantan-1-ylamino)-3-[3-(trifluoromethyl)phenyl]but-2-en-1-yl}-3,7-dimethyl-3,7-dihydro-1*H*-purine-2,6-dione (6c**).**



Prepared by general procedure C from **4a** and heating for 2h. Flash chromatography eluting with 30:1 v/v CHCl₃/MeOH gave the product **6c** (91%) as a colourless froth, mp 68–70°C; δ_{H} (300 MHz, CDCl₃): 7.86 (1H, s, phenyl-H), 7.75 (1H, d, *J* 7.7, phenyl-H), 7.52 (1H, s, purine-H), 7.47 (1H, d, *J* 7.7, phenyl-H), 7.39 (1H, t, *J* 7.7, phenyl-H), 5.90 (1H, t, *J* 7.1, NCH₂CH=), 4.90 (2H, d, *J* 7.1, NCH₂CH=), 3.99 (3H, s, NMe), 3.82 (2H, s, =CCH₂N), 3.59 (3H, s, NMe), 2.11 (3H, br s, 3 × adamantyl-CH), 1.79 (6H, br d, *J* 2.2, 3 × adamantyl-CH₂),


1.68 (6H, br d, J 1.6, 3 \times adamantyl-CH₂); δ_c (75 MHz, CDCl₃); 155.0, 151.4, 148.9, 142.5, 141.6, 140.9, 130.4 (J 32.1), 129.6, 128.6, 125.5, 124.2 (J 272.0), 123.8 (J 4.4), 123.2 (J 4.4), 107.6, 50.9, 42.5, 39.6, 39.4, 36.8, 33.6, 29.8, 29.7; ν_{max} /cm⁻¹ (film); 3310, 2907, 2849, 1702, 1661, 1604, 1550, 1487, 1455, 1415, 1334, 1258, 1234; m/z (ESI⁺) 528.3 (100%, MH⁺); (Found MH⁺, 528.2575. C₂₈H₃₃F₃N₅O₂ requires MH, 528.2581).

2',3',5'-Tri-O-acetyl-3-{(2Z)-4-(adamantan-1-ylamino)-3-[3,5-bis(trifluoromethyl)phenyl]but-2-en-1-yl}uridine (6d).



Prepared by general procedure C from **4b** and heating for 5h. Flash column chromatography eluting with 1:1 v/v EtOAc/*n*-hexane gave the product **6d** (77%) as a pale yellow gum; $[\alpha]_D + 19.5$ (c , 16 mg/1 mL CHCl₃); δ_H (300 MHz, CDCl₃); 8.00 (2H, s, 2 \times phenyl-H), 7.61 (1H, s, phenyl-H), 7.33 (1H, d, J 8.2, pyrimidinyl 6-H), 5.91 (1H, d, J 4.9, ribosyl 1-H), 5.78 (1H, t, J 7.1, NCH₂CH=), 5.74 (1H, d, J 8.2, pyrimidinyl 5-H), 5.28 (1H, dd, J 6.0 and 4.9, ribosyl 2-H), 5.23-5.19 (1H, m, ribosyl 3-H), 4.69 (2H, d, J 7.1, NCH₂CH=), 4.24 (3H, s, ribosyl 4-H and 5-CH₂), 3.62 (2H, s, =CCH₂N), 2.00 (9H, s, 2 \times OCOMe and 3 \times adamantyl-CH), 1.96 (3H, s, OCOMe), 1.64 (6H, br d, J 2.2, 3 \times adamantyl-CH₂), 1.56 (6H, br s, 3 \times adamantyl-CH₂); δ_c (75 MHz, CDCl₃); 170.1 (CO), 169.5 (2 \times CO), 161.9, 150.7, 144.0, 140.3, 137.5, 131.2 (q, J 33.2), 126.6 (brd, J 3.3), 125.9, 123.5 (q, J 237.1), 120.7 (q, J 3.9), 102.7, 88.7, 79.7, 73.0, 69.9, 62.8, 50.8, 42.5, 39.5, 39.4, 36.7, 29.6, 20.7, 20.4, 20.3; ν_{max} /cm⁻¹ (film); 3313, 3023, 2908, 2850, 1755, 1713, 1668, 1455, 1383, 1310, 1280, 1227; m/z (ESI⁺) 786.3 (100%, MH⁺); (Found MH⁺, 786.2941. C₃₇H₄₁F₆N₃O₉ requires MH, 786.2820).

2',3',5'-Tri-O-acetyl-3-{(2Z)-4-(adamantan-1-ylamino)-3-(3-chloro-4-fluorophenyl)but-2-en-1-yl}uridine (6e).




Prepared by general procedure C from **4b** and heating for 4h. Flash chromatography eluting with 1:1 v/v EtOAc/n-hexane gave the product **6e** (86%) as a pale yellow gum; $[\alpha]_D + 19.7$ (*c*, 14 mg/1 mL CHCl₃); δ_H (300 MHz, CDCl₃); 7.62 (1H, dd, *J* 7.1 and 2.2, phenyl-H), 7.44-7.39 (1H, m, phenyl-H), 7.40 (1H, d, *J* 8.2, pyrimidinyl 6-H), 7.05 (1H, t, *J* 8.5, phenyl-H), 6.00 (1H, d, *J* 4.4, ribosyl 1-H), 5.84 (1H, d, *J* 8.2, pyrimidinyl 5-H), 5.74 (1H, t, *J* 7.1, NCH₂CH=), 5.39 (1H, dd, *J* 5.5 and 4.4, ribosyl 2-H), 5.34-5.33 (1H, m, ribosyl 3-H), 4.75 (2H, d, *J* 7.1, NCH₂CH=), 4.35 (3H, s, ribosyl 4-H and 5-CH₂), 3.70 (2H, s, =CCH₂N), 2.13 (3H, s, OCOMe), 2.12 (3H, s, OCOMe), 2.10 (6H, s, OCOMe and 3 × adamantyl-CH), 1.74 (6H, br d, *J* 2.2, 3 × adamantyl-CH₂), 1.67 (6H, br s, 3 × adamantyl-CH₂); δ_c (75 MHz, CDCl₃); 170.1 (CO), 169.6 (2 × CO), 162.0, 157.5 (*J* 248.8), 150.7, 140.8, 139 (*J* 4.4), 137.4, 128.6, 126.1 (*J* 6.6), 123.9, 120.5 (*J* 17.7), 116.1 (*J* 21.0), 102.8, 88.8, 79.7, 73.0, 69.9, 62.8, 50.8, 42.5, 39.54, 39.51, 36.8, 29.6, 20.8, 20.5, 20.4; ν_{max}/cm^{-1} (film); 3312, 2906, 2849, 1751, 1711, 1668, 1497, 1455, 1386, 1310, 1228; *m/z* (ESI⁺) 702.3 (100%, MH⁺); (Found MH⁺, 702.2606. C₃₅H₄₂ClFN₃O₉ requires MH, 702.2588).

NOE data (CDCl₃) for **6e**:


Irradiated proton	% Enhancement				
	1-H	2-H	4-H	phenyl-H	adamantyl-CH ₂ (δ 1.74)
1-H		6.8	4.0	-	-
2-H	3.7		-	8.3 (δ 7.62) 6.6 (δ 7.41)	-
4-H	4.1	-		4.3 (δ 7.62) 3.3 (δ 7.41)	5.8

2',3',5'-Tri-*O*-acetyl-3-[*(2Z*)-4-(adamantan-1-ylamino)-3-(4-methylphenyl)but-2-en-1-yl]uridine (6f**).**



Prepared by general procedure C from **4b** and heating for 3h. Flash chromatography eluting with 1:1 v/v EtOAc/n-hexane gave the product **6f** (87%) as a pale yellow gum; $[\alpha]_D + 19.0$ (*c*, 11 mg/1 mL CHCl₃); δ_H (300 MHz, CDCl₃); 7.38 (2H, d, *J* 8.2, 2 × phenyl-H), 7.37 (1H, d, *J* 8.2, pyrimidinyl 6-H), 7.10 (2H, d, *J* 7.7, 2 × phenyl-H), 6.02 (1H, d, *J* 4.9, ribosyl 1-H), 5.82 (1H, d, *J* 8.2, pyrimidinyl 5-H), 5.76 (1H, t, *J* 7.1, NCH₂CH=), 5.37 (1H, dd, *J* 6.0 and 4.9, ribosyl 2-H), 5.35-5.31 (1H, m, ribosyl 3-H), 4.77 (2H, d, *J* 7.1, NCH₂CH=), 4.34 (3H, s, ribosyl 4-H and 5-CH₂), 3.79 (2H, s, =CCH₂N), 2.32 (3H, s, phenyl-Me), 2.13 (3H, s, OCOMe), 2.11 (3H, s, OCOMe), 2.08 (6H, s, OCOMe and 3 × adamantyl-CH), 1.73 (6H, br d, *J* 2.2, 3 × adamantyl-CH₂), 1.66 (6H, br d, *J* 2.2, 3 × adamantyl-CH₂); δ_c (75 MHz, CDCl₃); 170.1 (CO), 169.6 (2 × CO), 162.0, 150.7, 142.7, 138.4, 137.3, 137.1, 129.0, 126.2, 122.3, 102.9, 88.5, 79.6, 72.9, 69.9, 62.9, 50.8, 42.5, 39.8, 39.2, 36.8, 29.7, 21.1, 20.8, 20.5, 20.4; ν_{max}/cm^{-1} (film); 3313, 3022, 2906, 2849, 1748, 1712, 1668, 1511, 1455, 1371, 1310, 1228; *m/z* (ESI⁺) 664.3 (100%, MH⁺); (Found MH⁺, 664.3252. C₃₆H₄₆N₃O₉ requires MH, 664.3229).

3',5'-Di-O-acetyl-3-[*(2Z*)-4-(adamantan-1-ylamino)-3-phenylbut-2-en-1-yl]thymidine (6g).




Prepared by general procedure C from **4c** and heating for 3h. Flash chromatography eluting with 1:1 v/v EtOAc/n-hexane gave the product **6g** (99%) as a pale yellow gum; $[\alpha]_D + 5.2$ (*c*, 12 mg/1 mL CHCl₃); δ_H (300 MHz, CDCl₃); 7.50 (2H, dd, *J* 8.0 and 1.4, 2 × phenyl-H), 7.31-7.22 (3H, m, 3 × phenyl-H and pyrimidinyl 6-H), 6.37 (1H, dd, *J* 8.5 and 5.8, deoxyribosyl 1-H), 5.82 (1H, t, *J* 7.1, NCH₂CH=), 5.21 (1H, dt, *J* 6.6 and 2.2, deoxyribosyl 3-H), 4.82 (2H,

d, J 7.1, $\text{NCH}_2\text{CH}=$), 4.38 (1H, dd, J 12.1 and 3.8, deoxyribosyl 5-H_A), 4.32 (1H, dd, J 12.1 and 3.8, deoxyribosyl 5-H_B), 4.24 (1H, dt, J 6.6 and 3.8, deoxyribosyl 4-H), 3.83 (2H, s, =CCH₂N), 2.48 (1H, ddd, J 13.7, 5.5 and 1.6, deoxyribosyl 2-H_A), 2.20-2.08 (1H, ddd, J 13.7, 5.5 and 1.6, deoxyribosyl 5-H_B), 2.12 (3H, s, OCOMe), 2.10 (3H, s, OCOMe), 2.09 (3H, s, 3 \times adamantyl-CH), 1.95 (3H, s, pyrimidinyl 5-Me), 1.74 (6H, br d, J 2.2, 3 \times adamantyl-CH₂), 1.66 (6H, br d, J 2.2, 3 \times adamantyl-CH₂); δ_c (75 MHz, CDCl₃); 170.4, 170.2, 162.9, 150.7, 142.6, 141.4, 132.6, 128.3, 127.4, 126.3, 123.5, 110.8, 85.4, 82.0, 74.1, 63.9, 50.9, 42.6, 39.9, 39.3, 37.6, 36.8, 29.7, 20.9, 20.8, 13.5; $\nu_{\text{max}}/\text{cm}^{-1}$ (film); 3312, 3020, 2906, 2848, 1747, 1704, 1668, 1644, 1464, 1367, 1310, 1233; m/z (ESI⁺) 606.3 (100%, MH⁺); (Found MH⁺, 606.3194. C₃₄H₄₄N₃O₇ requires MH, 606.3174).

NOE data (CDCl₃) for **6g**:

Irradiated proton	% Enhancement				
	1-H	2-H	4-H	phenyl-H (δ 7.50)	adamantyl-CH ₂ (δ 1.74)
1-H		5.8	3.6	-	-
2-H	4.3		-	11.9	-
4-H	4.3	-		6.8	7.0


3',5'-Di-O-acetyl-3-{(2Z)-4-(adamantan-1-ylamino)-3-[4-(methoxycarbonyl)phenyl]but-2-en-1-yl}thymidine (6h).



Prepared by general procedure C from **4c** and heating for 4h. Flash chromatography eluting with 1:1 v/v EtOAc/n-hexane gave the product **6h** (93%) as a pale yellow gum; $[\alpha]_D + 7.6$ (c , 13 mg/1 mL CHCl₃); δ_H (300 MHz, CDCl₃); 7.96 (2H, d, J 8.5, 2 \times phenyl-H), 7.59 (2H, d, J 8.5, 2 \times phenyl-H), 7.29 (1H, s, pyrimidinyl 6-H), 6.38 (1H, dd, J 5.8 and 8.5, deoxyribosyl 1-H), 5.90 (1H, t, J 7.1, NCH₂CH=), 5.22 (1H, dt, J 6.6 and 2.2, deoxyribosyl 3-H), 4.83 (2H, d, J 7.1, NCH₂CH=), 4.39 (1H, dd, J 4.4 and 12.1, deoxyribosyl 5-H_A), 4.33 (1H, dd, J 3.3 and 12.1, deoxyribosyl 5-H_B), 4.25 (1H, dt, J 3.6 and 6.3, deoxyribosyl 4-H), 3.89 (3H, s, CO₂Me), 3.81 (2H, s, =CCH₂N), 2.49 (1H, ddd, J 1.6, 5.5 and 13.7, deoxyribosyl 2-H_A), 2.20

(1H, ddd, *J* 1.6, 6.6 and 13.7, deoxyribosyl 2-H_B), 2.12 (3H, s, OCOMe), 2.11 (3H, s, OCOMe), 2.10 (3H, s, 3 × adamantyl-CH), 1.96 (3H, s, pyrimidinyl 5-Me), 1.75 (6H, br d, *J* 2.2, 3 × adamantyl-CH₂), 1.67 (6H, br s, 3 × adamantyl-CH₂); δ_c (75 MHz, CDCl₃); 170.3, 170.1, 166.9, 162.9, 150.6, 146.1, 141.8, 132.8, 129.6, 128.8, 126.3, 125.3, 110.8, 85.4, 82.0, 74.1, 63.8, 52.0, 50.8, 42.5, 39.8, 39.2, 37.5, 36.8, 29.6, 20.9, 20.8, 13.4; ν_{max}/cm⁻¹ (film); 3311, 3018, 2906, 2848, 1746, 1704, 1669, 1645, 1606, 1465, 1366, 1278, 1233; *m/z* (ESI⁺) 664.3 (100%, MH⁺); (Found MH⁺, 664.3239. C₃₆H₄₆N₃O₉ requires MH, 664.3229).

3',5'-Di-O-acetyl-3-[*(2Z*)-4-(adamantan-1-ylamino)-3-(3,4-dichlorophenyl)but-2-en-1-yl]thymidine (6i**).**




Prepared by general procedure C from **4c** and heating for 2h. Flash chromatography eluting with 1:1 v/v EtOAc/n-hexane gave the product **6i** (87%) as a pale yellow gum; [α]_D + 7.7 (c, 11 mg/1 mL CHCl₃); δ_H (300 MHz, CDCl₃); 7.56 (1H, d, *J* 1.6, phenyl-H), 7.28 (1H, dd, *J* 8.2 and 1.6, 2 × phenyl-H), 7.19 (1H, d, *J* 8.2, phenyl-H), 7.18 (1H, s, pyrimidinyl 6-H), 6.27 (1H, dd, *J* 8.2 and 6.0, deoxyribosyl 1-H), 5.70 (1H, t, *J* 7.1, NCH₂CH=), 5.12 (1H, dt, *J* 6.6 and 2.2, deoxyribosyl 3-H), 4.68 (2H, d, *J* 7.1, NCH₂CH=), 4.28 (1H, dd, *J* 12.3 and 3.6, deoxyribosyl 5-H_A), 4.23 (1H, dd, *J* 12.3 and 3.6, deoxyribosyl 5-H_B), 4.15 (1H, dt, *J* 6.6 and 3.6, deoxyribosyl 4-H), 3.62 (2H, s, =CCH₂N), 2.38 (1H, ddd, *J* 14.3, 6.6 and 2.2, deoxyribosyl 2-H_A), 2.09 (1H, ddd, *J* 14.3, 8.2 and 1.6, deoxyribosyl 2-H_B), 2.02 (3H, s, OCOMe), 2.00 (6H, s, OCOMe and 3 × adamantyl-CH), 1.86 (3H, s, pyrimidinyl 5-Me), 1.64 (6H, br d, *J* 2.2, 3 × adamantyl-CH₂), 1.56 (6H, br s, 3 × adamantyl-CH₂); δ_c (75 MHz, CDCl₃); 170.3, 170.1, 162.9, 150.6, 141.8, 140.5, 132.8, 132.2, 130.9, 130.0, 128.3, 125.7, 124.8, 110.8, 85.4, 82.0, 74.1, 63.8, 50.9, 42.5, 39.7, 39.3, 37.5, 36.8, 29.6, 20.9, 20.8, 13.4; ν_{max}/cm⁻¹ (film); 3310, 3018, 2906, 2848, 1746, 1702, 1670, 1644, 1550, 1466, 1366, 1336, 1310, 1233; *m/z* (ESI⁺) 674.2 (100%, MH⁺); (Found MH⁺, 674.2410. C₃₄H₄₂Cl₂N₃O₇ requires MH, 664.3229).

General Procedure D: Pd catalysed 9-component cascades.

A mixture of substituted allene **4** (4 equiv.), 1,3,5,7-tetrakis-(4-iodophenyl)adamantane **3** (1 equiv.), nucleophile **7** (4.4 equiv.), $\text{Pd}_2(\text{dba})_3$ (2.5 mol%), TFP (tri-(2-furyl)phosphine) (10 mol%), and K_2CO_3 (6 equiv.) in MeCN or DMF was stirred and heated at 80 °C (oil bath temperature) for 3-32h. The mixture was filtered and the inorganic precipitate washed with MeCN. The solvent was removed under reduced pressure, the residue dissolved in CHCl_3 and washed with H_2O . The organic layer was dried over anhydrous MgSO_4 , filtered, and the filtrate evaporated under reduced pressure. The residue was purified by flash chromatography.

1,1',1'',1'''-[Tricyclo[3.3.1.1^{3,7}]decane-1,3,5,7-tetrayltetrakis(4,1-phenylene{(2Z)-4-[3-(3-isopropyl-5-methyl-4*H*-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]-oct-8-yl]but-2-ene-3,1-diyl}]-tetrakis(3,7-dimethyl-3,7-dihydro-1*H*-purine-2,6-dione) (8a).




Prepared by general procedure D from **4a** in MeCN and heating for 24h. Flash chromatography gradient eluting with 20:1 v/v $\text{CHCl}_3/\text{MeOH}$ then 15:1 v/v $\text{CHCl}_3/\text{MeOH}$ gave the product **8a** (52%) as a colourless froth, mp 199-201°C; δ_{H} (300 MHz, CDCl_3); 7.54 (4H, s, 4 × purine-H), 7.46 (8H, d, *J* 8.2, 8 × phenyl-H), 7.37 (8H, d, *J* 8.2, 8 × phenyl-H), 5.88 (4H, t, *J* 6.2, 4 × $\text{NCH}_2\text{CH=}$), 4.93 (8H, d, *J* 6.2, 4 × $\text{NCH}_2\text{CH=}$), 4.24 (4H, m, 4 × azabicyclooctyl-H), 3.99 (12H, s, 4 × purine- NCH_3), 3.68 (8H, s, 4 × = CCH_2N), 3.58 (12H, s,

4 × purine-NCH₃), 3.46 (8H, br s, 8 × azabicyclooctyl-H), 2.96 (4H, m, 4 × triazolyl 3-CH(CH₃)₂), 2.37 (12H, s, 4 × triazolyl 5-CH₃), 2.21 (8H, br dd, *J* 8.7 and 3.6, 8 × azabicyclooctyl-H), 2.1 (20H, br s, 8 × azabicyclooctyl-H + 6 × adamantyl-CH₂), 1.66 (16H, br d, *J* 7.7, 16 × azabicyclooctyl-H), 1.32 (24H, d, *J* 6.7, 4 × triazolyl 3-CH(CH₃)₂); δ_c (75 MHz, CDCl₃) 157.6, 153.5, 149.9, 149.3, 147.4, 146.7, 140.2, 138.9, 138.5, 125.3, 124.8, 123.0, 106.2, 57.2, 49.7, 45.8 (2 × C), 38.2, 37.5, 36.0, 32.2, 28.3, 25.2, 24.2, 20.2, 11.4; ν_{max}/cm⁻¹ (film); 3384, 2935, 1704, 1661, 1603, 1549, 1513, 1455, 1415, 1357, 1314, 1286, 1234; *m/z* (ESI⁺) 2321.3 (30%, [M+Na]⁺); (Found [M+Na]⁺, 2321.2911. C₁₃₀H₁₆₁NaN₃₂O₈ requires [M+Na]⁺, 2321.3018); 2298.3 (28%, [M+H]⁺); (Found [M+H]⁺, 2298.3056. C₁₃₀H₁₆₁N₃₂O₈ requires [M+H]⁺, 2298.3170); 1171.6 (34%, [M+2Na]²⁺); (Found [M+2Na]²⁺, 1171.6477. C₁₃₀H₁₆₀Na₂N₃₂O₈ requires [M+2Na]²⁺, 1171.6441); 1160.7 (80%, [M+H+Na]²⁺); (Found [M+H+Na]²⁺, 1160.6560. C₁₃₀H₁₆₁NaN₃₂O₈ requires [M+H+Na]²⁺, 1160.6531); 1150.2 (100%, [M+2H]²⁺); (Found [M+2H]²⁺, 1149.6660. C₁₃₀H₁₆₂N₃₂O₈ requires [M+2H]²⁺, 1149.6621).

NOE data (CDCl₃) for **8a**.


Irradiated proton	% Enhancement				
	1-H	2-H	4-H	Ph-H	Azabicyclooctyl-H
1-H		-8.7	-	-	-
2-H	-6.3		-	-	-
4-H	-1.0	-		-2.2 (δ 7.46)	-2.7 (δ 3.46)

1,1',1'',1'''-(Tricyclo[3.3.1.1^{3,7}]decane-1,3,5,7-tetrayltetrakis{4,1-phenylene[(2Z)-4-(adamantan-1-ylamino)but-2-ene-3,1-diyll]})tetrakis(3,7-dimethyl-3,7-dihydro-1*H*-purine-2,6-dione) (8b).




Prepared by general procedure D from **4a** in DMF and heating for 24h. Flash chromatography eluting with 10:1 v/v CHCl₃/MeOH gave the product **8b** (87%) as a colourless froth, mp 217-219°C; δ_H (300 MHz, CDCl₃); 7.50 (4H, s, 4 × purine-H), 7.49 (8 H, d, *J* 7.6, 8 × phenyl-H), 7.36 (8 H, d, *J* 7.6, 8 × phenyl-H), 5.85 (4H, t, *J* 7.2, 4 × NCH₂CH=), 4.87 (8H, d, *J* 7.2, 4 × NCH₂CH=), 3.98 (12H, s, 4 × NMe), 3.85 (8H, s, 4 × =CCH₂N), 3.57 (12H, s, 4 × NMe), 2.65 (4H, br s, 4 × NH), 2.08 (28H, br s, 12 × adamantyl-CH + 6 × adamantyl-CH₂ + 4 × NH), 1.77 (24H, br s, 12 × adamantyl-CH₂), 1.66 (24H, br s, 12 × adamantyl-CH₂); δ_C (75 MHz, CDCl₃); 155.1, 151.4, 148.8, 148.6, 141.5, 141.2, 138.8, 126.3, 125.0, 124.1, 107.7, 51.3, 47.1, 42.2, 39.8, 39.0, 38.9, 36.8, 33.6, 29.8, 29.6; ν_{max}/cm⁻¹ (film); 2903, 2847, 2366, 1704, 1660, 1604, 1549, 1486, 1454, 1413, 1357, 13101286, 1233; *m/z* (ESI⁺) 1966.1097 (3%, [M+H]⁺); (Found [M+H]⁺, 1966.1097. C₁₁₈H₁₄₁N₂₀O₈ requires [M+H]⁺, 1966.1236); 983.6 (93%, [M+2H]²⁺); (Found [M+2H]²⁺, 983.5666. C₁₁₈H₁₄₂N₂₀O₈ requires [M+2H]²⁺, 983.5654); 656.0 (100%, [M+3H]³⁺); (Found [M+3H]³⁺, 656.0474. C₁₁₈H₁₄₃N₂₀O₈ requires [M+3H]³⁺, 656.0460).

Tetramethyl (2S,2'S,2''S,2'''S)-2,2',2'',2'''-(tricyclo[3.3.1.1^{3,7}]decane-1,3,5,7-tetrayltetrakis{4,1-phenylene[(2Z)-4-(3,7-dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-1-yl)but-2-ene-2,1-diyl]imino})tetrakis[3-(1H-indol-3-yl)propanoate] (8c).



Prepared by general procedure D from **4a** in MeCN and heating for 24h. Flash chromatography eluting with 9:1 v/v CHCl₃/MeOH gave the product **8c** (45%) as a colourless froth, mp 129-131°C; [α]_D + 9.1; δ_H (300 MHz, CDCl₃); 7.54 (4H, d, *J* 7.6, 4 × indolyl-H), 7.44 (4H, s, 4 × purine-H), 7.31 (8 H, d, *J* 8.6, 8 × phenyl-H), 7.24 (8 H, d, *J* 8.6, 8 × phenyl-H), 7.17 (4H, dd, *J* 8.6 and 1.0, 4 × indolyl-H), 7.05 (8H, m, 8 × indolyl-H), 6.89 (4H, d, *J* 1.9, 4 × indolyl-H), 5.82 (4H, t, *J* 6.8, 4 × NCH₂CH=), 4.79 (8H, d, *J* 6.8, 4 × NCH₂CH=), 9.95-3.90 (4H, m, CHCO₂Me), 3.90 (12H, s, 4 × NMe), 3.75 (4H, d, *J* 6.7, 4 × =CCH_AN), 3.72 (4H, d, *J* 6.7, 4 × =CCH_BN), 3.65 (12H, s, CO₂Me), 3.52 (12H, s, 4 × NMe), 3.16 (4H, dd, *J* 14.3 and 6.6, 4 × CH_ACHCO₂Me), 3.05 (4H, dd, *J* 14.3 and 6.6, 4 × CH_BCHCO₂Me), 2.00 (16H, br s, 6 × adamantyl-CH₂ + 4 × NH); δ_c (75 MHz, CDCl₃); 175.4, 155.0, 151.4, 148.8, 148.4, 141.5, 140.5, 138.6, 136.1, 127.4, 126.3, 124.8 (2 × C), 123.0, 121.8, 119.3, 118.8, 111.3, 111.1, 107.6, 61.7, 51.8, 47.1, 46.6, 39.6, 38.9, 33.6, 32.0, 29.7; ν_{max}/cm⁻¹ (film); 3330, 2926, 2853, 1701, 1659, 1549, 1456, 1355, 1233; *m/z* (ESI⁺) 2234.0 (10%, [M+H]⁺); (Found [M+H]⁺, 2234.0270. C₁₂₆H₁₂₉N₂₄O₁₆ requires [M+H]⁺, 2234.0013); 1117.5 (100%, [M+2H]²⁺); (Found [M+2H]²⁺, 1117.5083. C₁₂₆H₁₃₀N₂₄O₁₆ requires [M+2H]²⁺, 1117.5043); 745.3 (40%, [M+3H]³⁺); (Found [M+3H]³⁺, 745.3410. C₁₂₆H₁₃₁N₂₄O₁₆ requires [M+3H]³⁺, 745.3386).


Tetramethyl (2*S*,2'*S*,2''*S*,2'''*S*)-2,2',2'',2'''-(tricyclo[3.3.1.1^{3,7}]decane-1,3,5,7-tetrayltetrakis{4,1-phenylene[(2*Z*)-4-(3,7-dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-1*H*-purin-1-yl)but-2-ene-2,1-diyl]imino})tetrakis(3-hydroxypropanoate) (8d).



Prepared by general procedure D from **4a** in MeCN and heating for 32h. Flash chromatography eluting with 10:1 v/v CHCl₃/MeOH gave the product **8d** (49%) as a colourless froth, mp 136–138°C; [α]_D + 1.3; δ_H (300 MHz, CDCl₃): 7.50 (4H, s, 4 × purine-H), 7.44 (8H, d, *J* 8.5, 8 × phenyl-H), 7.38 (8H, d, *J* 8.5, 8 × phenyl-H), 5.91 (4H, t, *J* 7.1, 4 × NCH₂CH=), 4.95 (4H, dd, *J* 14.3 and 7.1, 4 × NCH_ACH=), 4.87 (4H, dd, *J* 14.3 and 7.1, 4 × NCH_BCH=), 3.98 (12H, s, 4 × NMe), 3.97 (4H, d, *J* 12.1, 4 × =CCH_AN), 3.87 (4H, dd, *J* 10.4 and 3.8, 4 × CHCH_AOH), 3.80 (4H, d, *J* 12.1, 4 × =CCH_BN), 3.75 (12H, s, 3 × CO₂Me), 3.63 (4H, dd, *J* 10.4 and 3.8, 4 × CHCH_BOH), 3.57 (12H, s, 4 × NMe), 3.58–3.51 (4H, m, 4 × NHCHCH₂), 2.07 (12H, br s, 6 × adamantyl-CH₂); δ_C (75 MHz, CDCl₃): 173.2, 155.1, 151.4, 148.9, 148.7, 141.6, 140.4, 138.4, 126.2, 125.1, 124.8, 107.7, 62.7, 62.5, 52.1, 47.1, 46.3, 39.6, 39.0, 33.7, 29.8; ν_{max}/cm^{−1} (film): 3457, 2949, 1733, 1704, 1660, 1604, 1550, 1455, 1355, 1315, 1233; *m/z* (ESI⁺) 1837.8 (14%, [M+H]⁺); (Found [M+H]⁺, 1837.8143. C₉₄H₁₀₉N₂₀O₂₀ requires M⁺, 1837.8122); 919.4 (100%, [M+2H]²⁺); (Found [M+2H]²⁺, 919.4139. C₉₄H₁₁₀N₂₀O₂₀ requires [M+2H]²⁺, 919.4097); 613 (23%, [M+3H]³⁺); (Found [M+3H]³⁺, 613.2781. C₉₄H₁₁₁N₂₀O₂₀ requires [M+3H]³⁺, 613.2756).


Tetramethyl (2*S*,2'*S*,2''*S*,2'''*S*)-2,2',2'',2'''-(tricyclo[3.3.1.1^{3,7}]decane-1,3,5,7-tetrayltetrakis{4,1-phenylene[(2*Z*)-4-(3,7-dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-1*H*-purin-1-yl)but-2-ene-2,1-diyl]imino})tetrakis(3-hydroxypropanoate) (8d).

purin-1-yl)but-2-ene-2,1-diyl]imino(1-oxoethane-2,1-diyl)imino}tetrakis(4-methylpentanoate) (8e**).**



Prepared by general procedure D from **4a** in MeCN and heating for 26h. Flash chromatography eluting with 20:1 v/v CHCl₃/MeOH gave the product **8e** (55%) as a colourless froth, mp 106-108°C; [α]_D + 0.7; δ_H (300 MHz, CDCl₃); 7.66 (4H, d, *J* 8.2, 4 × CONH), 7.53 (4H, s, 4 × purine-H), 7.41 (8H, d, *J* 8.5, 8 × phenyl-H), 7.37 (8H, d, *J* 8.5, 8 × phenyl-H), 5.85 (4H, t, *J* 7.1, 4 × NCH₂CH=), 4.91 (4H, dd, *J* 14.3 and 7.1, 4 × NCH_ACH=), 4.83 (4H, dd, *J* 14.3 and 7.1, 4 × NCH_BCH=), 4.64 (4H, td, *J* 8.2 and 4.4, 4 × CONHCH), 3.99 (12H, s, 4 × purine 7-NMe), 3.93 (4H, d, *J* 12.9, 4 × =CCH_AN), 3.82 (4H, d, *J* 12.9, 4 × =CCH_BN), 3.68 (12H, s, 3 × CO₂Me), 3.58 (12H, s, 4 × purine 3-NMe), 3.35 (8H, br s, 4 × NHCH₂CO), 2.08 (12H, br s, 6 × adamantyl-CH₂), 2.04 (4H, br s, 4 × NH), 1.67-1.44 (12H, m, CH₂CHMe₂), 0.90 (12H, d, *J* 4.4, 4 × CHMe_A), 0.88 (12H, d, *J* 4.4, 4 × CHMe_B); δ_C (75 MHz, CDCl₃); 173.4, 171.9, 155.0, 151.4, 148.9, 148.6, 141.6, 140.7, 138.7, 126.5, 125.1, 125.0, 107.7, 52.2 (2C, Me and CH₂), 50.1, 47.9, 47.2, 41.2, 39.5, 39.0, 33.7, 29.8, 24.9, 23.0, 21.8; ν_{max}/cm⁻¹ (film); 3334, 3008, 2955, 1742, 1705, 1660, 1604, 1549, 1512, 1452, 1355, 1315, 1234; *m/z* (ESI⁺) 2170.1 (6%, [M+H]⁺); (Found [M+H]⁺, 2170.1061. C₁₁₄H₁₄₅N₂₄O₂₀ requires M⁺, 2170.0946); 1085.6 (100%, [M+2H]²⁺); (Found [M+2H]²⁺, 1085.5578. C₁₁₄H₁₄₆N₂₄O₂₀ requires [M+2H]²⁺, 1085.5567); 724.0 (63%, [M+3H]³⁺); (Found [M+3H]³⁺, 724.0418. C₁₁₄H₁₄₇N₂₄O₂₀ requires [M+3H]³⁺, 724.0402).


1,1',1'',1'''-[Tricyclo[3.3.1.1^{3,7}]decane-1,3,5,7-tetrayltetrakis(4,1-phenylene{(2Z)-4-[3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]oct -8-yl]but-2-ene-3,1-diyl})]tetrakis(2', 3', 5'-tri-O-acetyluridine) (8f).



Prepared by general procedure D from **4b** in MeCN and heating for 5h. Flash column chromatography gradient eluting with EtOAc and then 2:1 v/v EtOAc/MeOH gave the product **8f** (56%) as a colourless froth, mp 134-136°C; $[\alpha]_D + 18.9$ (*c*, 10 mg/1 mL CHCl₃); δ_H (300 MHz, CDCl₃); 7.45 (8H, d, *J* 8.4, 8 × phenyl-H), 7.40 (8H, d, *J* 8.4, 8 × phenyl-H), 7.38 (4H, s, 4 × pyrimidinyl 6-H), 6.00 (4H, d, *J* 4.6, 4 × ribosyl 1-H), 5.83 (4H, s, 4 × pyrimidinyl 5-H), 5.82 (4H, t, *J* 7.0, 4 × NCH₂CH=), 5.40-5.32 (8H, m, 4 × ribosyl 2-H + 4 × ribosyl 3-H), 4.86 (4H, dd, *J* 14.8 and 7.0, 4 × NCH_ACH=), 4.82 (4H, dd, *J* 14.8 and 7.0, 4 × NCH_BCH=), 4.35 (12H, s, 4 × ribosyl 4-H + 4 × ribosyl 5-CH₂), 4.26-4.21 (4H, m, 4 × azabicyclooctyl-H), 3.62 (8H, s, 4 × =CCH₂N), 3.43 (8H, br s, 8 × azabicyclooctyl-H), 2.98-2.90 (4H, m, 4 × triazolyl 3-CH(CH₃)₂), 2.37 (12H, s, 4 × triazolyl 5-CH₃), 2.18-2.02 (28H, m, 16 × azabicyclooctyl-H + 6 × adamantyl-CH₂), 2.13 (12H, s, 4 × ribosyl OMe), 2.12 (12H, s, 4 × ribosyl OMe), 2.09 (12H, s, 4 × ribosyl OMe), 1.65 (16H, br d, *J* 7.7, 16 × azabicyclooctyl-H), 1.32 (24H, d, *J* 6.7, 4 × triazolyl 3-CH(CH₃)₂); δ_C (75 MHz, CDCl₃); 170.1 (CO), 169.6 (2 × CO), 162.0, 159.1, 150.7, 150.67, 148.2, 141.0, 139.9, 137.5, 126.8, 125.2, 124.5, 102.8, 88.8, 79.6, 72.9, 69.9, 62.9, 58.7, 51.2, 47.3 (2 × C), 39.6, 39.0, 37.4, 26.6, 25.7, 21.6, 20.8, 20.5, 12.9 (One aliphatic carbon could not be located due to peak

overlaps); ν_{max} /cm⁻¹ (film); 2934, 1750, 1711, 1669, 1512, 1455, 1386, 1228; m/z (ESI⁺) 3058.5 (2%, [M+H]⁺); (Found [M+H]⁺, 3058.4522. C₁₆₂H₂₀₁N₂₄O₃₆ requires MH, 3058.4630); 1551.7 (100%, [M+2Na]²⁺); (Found [M+2Na]²⁺, 1551.7152. C₁₆₂H₂₀₀Na₂N₂₄O₃₆ requires [M+2Na]²⁺, 1551.7171); 1529.7 (61%, [M+2H]²⁺); (Found [M+2H]²⁺, 1529.7358. C₁₆₂H₂₀₂N₂₄O₃₆ requires [M+2H]²⁺, 1529.7351).

1,1',1'',1'''-(Tricyclo[3.3.1.1^{3,7}]decane-1,3,5,7-tetrayltetrakis{4,1-phenylene[(2Z)-4-(8-fluoro-1,3,4,5-tetrahydro-2H-pyrido[4,3-*b*]indol-2-yl)but-2-ene-3,1-diyl]})tetrakis(2', 3', 5'-tri-*O*-acetyluridine) (8g).




Prepared by general procedure D from **4b** in MeCN and heating for 3h. Flash column chromatography eluting with 30:1 v/v EtOAc/MeOH gave the product **8g** (62 %) as a colourless froth, mp 144–146°C; $[\alpha]_D + 24.7$ (c , 12 mg/1 mL CHCl₃); δ_H (300 MHz, CDCl₃); 8.02 (4H, br s, 4 × NH), 7.38 (8H, d, J 7.9, 8 × phenyl-H), 7.36 (4H, d, J 8.2, 4 × pyrimidinyl 6-H), 6.98 (8H, d, J 7.9, 8 × phenyl-H), 7.07 (4H, dd, J 8.6 and 4.5, 4 × pyridoindolyl-H), 6.98 (4H, dd, J 9.5 and 1.8, 4 × pyridoindolyl-H), 6.76 (4H, dt, J 9.1 and 2.3, 4 × pyridoindolyl-H), 6.04 (4H, d, J 4.4, 4 × ribosyl 1-H), 5.85 (4H, t, J 6.4, 4 × NCH₂CH=), 5.82 (4H, d, J 8.2, 4 × pyrimidinyl 5-H), 5.34 (8H, dd, J 8.7 and 6.1, 4 × ribosyl 2-H + 4 ×

ribosyl 3-H), 4.81 (8H, d, *J* 6.4, 4 × NCH₂CH=), 4.33 (12H, s, 4 × ribosyl 4-H + 4 × ribosyl 5-CH₂), 3.76 (8H, br s, 4 × =CCH₂N), 3.64 (8H, br s, 4 × pyridoindolyl 1-CH₂), 2.81 (8H, br s, 4 × pyridoindolyl-CH₂), 2.60 (8H, br s, 4 × pyridoindolyl-CH₂), 2.12 (12H, s, 4 × ribosyl OMe), 2.11 (12H, s, 4 × ribosyl OMe), 2.05 (12H, s, 4 × ribosyl OMe), 1.85 (12H, br s, 6 × adamanyl-CH₂); δ_c (75 MHz, CDCl₃); 170.4 (CO), 169.8 (2 × CO), 162.2, 157.7 (*J* 232.2), 150.9, 148.6, 140.3, 139.6, 137.4, 134.6, 132.5, 126.6 (*J* 9.2), 126.57, 125.9, 125.0, 111.2 (*J* 9.2), 109.0 (*J* 4.5), 108.8 (*J* 25.3), 103.8, 102.9 (*J* 25.3), 88.5, 79.9, 73.1, 70.2, 63.2, 49.8, 49.3, 47.1, 40.0, 39.0, 29.9, 23.8, 21.0, 20.7, 20.6; ν_{max}/cm⁻¹ (film); 3373, 3023, 2929, 1748, 1712, 1667, 1483, 1455, 1372, 1325, 1229; *m/z* (ESI⁺) 2882.1 (10%, [M+H]⁺); (Found [M+H]⁺, 2882.0786. C₁₅₄H₁₅₇F₄N₁₆O₃₆ requires MH, 2882.0877); 1441.5 (100%, [M+2H]²⁺); (Found [M+2H]²⁺, 1441.5480. C₁₅₄H₁₅₈F₄N₁₆O₃₆ requires [M+2H]²⁺, 1441.5475); *m/z* (ESI⁺) 961.4 (100%, [M+3H]³⁺); (Found [M+3H]³⁺, 961.4. C₁₅₄H₁₅₉F₄N₁₆O₃₆ requires [M+3H]³⁺, 961.3674).

NOE data (CDCl₃) for **8g**.

Irradiated proton	% Enhancement				
	1-H	2-H	4-H	Ph-H	pyridoindolyl-H
1-H		-11.4	-4.6	-	-1.7 (δ 3.64)
2-H	-7.3		-	-6.5 (δ 7.38)	-
4-H	-7.0	-		-7.9 (δ 7.38)	-4.9 (δ 3.64) -5.8 (δ 2.81) -2.1 (δ 2.60)

1,1',1'',1'''-[Tricyclo[3.3.1.1^{3,7}]decane-1,3,5,7-tetrayltetrakis(4,1-phenylene{(2Z)-4-[3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]oct-8-yl]but-2-ene-3,1-diyl})]tetrakis(3', 5'-di-*O*-acetylthymidine) (8h).




Prepared by general procedure D from **4c** in MeCN and heating for 4h. Flash chromatography gradient eluting with 4:1 v/v EtOAc/MeOH and then 1:1 v/v EtOAc/MeOH gave the product **8h** (69%) as a colourless froth, mp 146-148°C; $[\alpha]_D + 2.6$ (*c*, 11 mg/1 mL CHCl₃); δ_H (300 MHz, CDCl₃); 7.46 (8H, d, *J* 8.6, 8 × phenyl-H), 7.37 (8H, d, *J* 8.6, 8 × phenyl-H), 7.29 (4H, s, 4 × pyrimidinyl 6-H), 6.37 (4H, dd, *J* 5.6 and 8.4, 4 × deoxyribosyl 1-H), 5.85 (4H, t, *J* 6.7, 4 × NCH₂CH=), 5.22 (4H, dd, *J* 4.5 and 2.1, 4 × deoxyribosyl 3-H), 4.87 (8H, d, *J* 6.7, 4 × NCH₂CH=), 4.37 (4H, dd, *J* 12.2 and 3.6, 4 × deoxyribosyl 5-H_A), 4.35 (4H, dd, *J* 12.2 and 3.6, 4 × deoxyribosyl 5-H_B), 4.27-4.24 (8H, m, 4 × azabicyclooctyl-H + 4 × deoxyribosyl 4-H), 3.67 (8H, s, 4 × =CCH₂N), 3.44 (8H, br s, 8 × azabicyclooctyl-H), 2.98-2.93 (4H, m, 4 × triazolyl 3-CH(CH₃)₂), 2.51 (4H, dd, *J* 5.6 and 1.5, 4 × deoxyribosyl 2-H_A), 2.46 (4H, dd, *J* 5.6 and 1.5, 4 × deoxyribosyl 2-H_B), 2.37 (12H, s, 4 × triazolyl 5-CH₃), 2.23-2.05 (28H, m, 16 × azabicyclooctyl-H + 6 × adamantyl-CH₂), 2.14 (12H, s, 4 × deoxyribosyl OMe), 2.12 (12H, s, 4 × deoxyribosyl OMe), 1.96 (12H, s, 4 × pyrimidinyl 5-Me), 1.66 (16H, br d, *J* 7.9, 16 × azabicyclooctyl-H), 1.32 (24H, d, *J* 6.9, 4 × triazolyl 3-CH(CH₃)₂); δ_c (75 MHz, CDCl₃); 170.8, 170.6, 163.4, 159.5, 151.1, 151.0, 148.6, 141.2, 140.3, 133.2, 127.1, 125.9, 124.9, 111.2, 85.9, 82.5, 74.5, 64.3, 59.1, 51.6, 47.7 (2 x C), 40.2, 39.4, 37.9, 37.8, 27.1, 26.1, 22.0, 21.3, 21.2, 13.9, 13.3; ν_{max}/cm^{-1} (film); 3333, 2932, 1746, 1703, 1668, 1645, 1513, 1467, 1366, 1235; *m/z* (ESI⁺) 2904.5 (8%, [M+Na]⁺); (Found [M+Na]⁺, 2904.4779. C₁₅₈H₂₀₀NaN₂₄O₂₈ requires MNa, 2904.4856); 2882.5 (15%,

[M+H]⁺); (Found [M+H]⁺, 2882.4986. C₁₅₈H₂₀₁N₂₄O₂₈ requires MH, 2882.5037); 1493.7 (68%, [M+2Na]²⁺); (Found [M+2Na]²⁺, 1463.7397. C₁₅₈H₂₀₀NaN₂₄O₂₈ requires [M+2Na]²⁺, 1463.7374); 1441.8 (100%, [M+2H]²⁺); (Found [M+2H]²⁺, 1441.7615. C₁₅₈H₂₀₂N₂₄O₂₈ requires [M+2H]²⁺, 1441.7555).

NOE data (CDCl₃) for **8h**.

Irradiated proton	% Enhancement				
	1-H	2-H	4-H	Ph-H	Azabicyclooctyl-H
1-H		-9.5	-1.1	-	-
2-H	-5.1		-	-	-
4-H	-2.1	-		-1.9 (δ 7.46)	-4.3 (δ 3.44)

1,1',1'',1'''-(Tricyclo[3.3.1.1^{3,7}]decane-1,3,5,7-tetrayltetrakis{4,1-phenylene[(2Z)-4-(8-fluoro-1,3,4,5-tetrahydro-2H-pyrido[4,3-*b*]indol-2-yl)but-2-ene-3,1-diyl]})tetrakis(3', 5'-di-*O*-acetylthymidine) (8i).



Prepared by general procedure D from **4c** in MeCN and heating for 6h. Flash column chromatography eluting with 20:1 v/v EtOAc/MeOH gave the product **8i** (74%) as a colourless froth, mp 155-157°C; $[\alpha]_D + 6.2$ (*c*, 11 mg/1 mL CHCl₃); δ_H (300 MHz, CDCl₃); 8.18 (4H, br s, 4 × NH), 7.36 (8H, d, *J* 8.1, 8 × phenyl-H), 7.26 (4H, s, 4 × pyrimidinyl 6-H), 7.13 (8H, d, *J* 8.1, 8 × phenyl-H), 7.02 (4H, dd, *J* 8.5 and 4.4, 4 × pyridoindolyl-H), 6.95 (4H,

dd, *J* 9.6 and 1.9, 4 × pyridoindolyl-H), 6.73 (4H, dt, *J* 9.2 and 2.4, 4 × pyridoindolyl-H), 6.36 (4H, dd, *J* 7.9 and 5.9, 4 × deoxyribosyl 1-H), 5.85 (4H, t, *J* 6.5, 4 × NCH₂CH=), 5.20 (4H, dd, *J* 4.4 and 1.8, 4 × deoxyribosyl 3-H), 4.82 (8H, d, *J* 6.5, 4 × NCH₂CH=), 4.38 (4H, dd, *J* 12.2 and 3.7, 4 × deoxyribosyl 5-H_A), 4.30 (4H, dd, *J* 12.2 and 3.7, 4 × deoxyribosyl 5-H_B), 4.23 (4H, dd, *J* 5.8 and 3.2, 4 × deoxyribosyl 4-H), 3.76 (8H, br s, 4 × =CCH₂N), 3.61 (8H, br s, 4 × pyridoindolyl 1-CH₂), 2.77 (8H, br s, 4 × pyridoindolyl-CH₂), 2.50-2.43 (16H, br m, 4 × pyridoindolyl-CH₂ + 4 × deoxyribosyl 2-CH₂), 2.12 (12H, s, 4 × deoxyribosyl OMe), 2.10 (12H, s, 4 × deoxyribosyl OMe), 1.95 (12H, s, 4 × pyrimidinyl 5-Me), 1.77 (12H, br s, 6 × adamanyl-CH₂); δ_c (75 MHz, CDCl₃); 169.3, 169.1, 161.8, 156.3 (*J* 232.2), 149.5, 147.2, 138.9, 138.3, 133.2, 131.5, 131.2, 125.2 (*J* 9.2), 125.15, 124.7, 123.6, 109.7 (*J* 9.2), 109.5, 107.4 (*J* 4.5), 107.3 (*J* 25.2), 101.4 (*J* 23.0), 84.3, 80.9, 73.0, 62.7, 54.5, 48.6, 47.9, 45.7, 38.8, 37.5, 36.4, 22.3, 19.7, 19.66, 12.3; ν_{max}/cm⁻¹ (film); 3346, 2927, 1744, 1702, 1643, 1465, 1366, 1325, 1232; *m/z* (ESI⁺) 2706.1 (2%, [M+H]⁺); (Found [M+H]⁺, 2706.1237. C₁₅₀H₁₅₇F₄N₁₆O₂₈ requires MH, 2705.1284); *m/z* (ESI⁺) 1353.6 (59%, [M+2H]²⁺); (Found [M+2H]²⁺, 1353.5679. C₁₅₀H₁₅₈F₄N₁₆O₂₈ requires [M+2H]²⁺, 1353.5678); 902.7 (100%, [M+3H]³⁺); (Found [M+3H]³⁺, 902.7141. C₁₅₀H₁₅₉F₄N₁₆O₂₈ requires [M+3H]³⁺, 902.7143).

References

1. H. B. Lazrek, J. W. Engels, W. Pfleiderer, *Nucleosides and Nucleotides*, **1998**, 17, 1851-1856.
2. J. Kuang, S. Ma, *J. Org. Chem.* **2009**, 74, 1763-1765.
3. D. Bruyere, R. Grigg, J. Hinsley, R. K. Hussain, S. Korn, C. Orgaz De La Cierva, V. Sridharana , J. Wanga, *Tetrahedron Lett.* **2003**, 44, 8669-8672.
4. A. Casaschi, R. Grigg, J. M. Sansano, *Tetrahedron* **2000**, 56, 7553-7560.
5. J. W. Daly, W. L. Padgett, M. T. Shamim, *J. Med. Chem.* **1986**, 29, 1305-1308.

School of Chemistry Mass Spectrometry Service



Comment	EE-90	Operator	Tanya						
Sample Name	EE-90	Acquisition Date	27/09/2011 10:04:51						
Analysis Name	D:\Data\Sept.2011\EE-90_1-B,6_01_14764.d								
Method	steve200-2500lc.m								
Instrument	micrOTOF	Source Type	ESI	Ion Polarity	Positive	Scan Begin	50 m/z	Scan End	2500 m/z




Fig. (1): HRMS of **8a** using autosampler technique.

School of Chemistry Mass Spectrometry Service



Comment	EE-103DMF	Operator	Tanya
Sample Name	116878	Acquisition Date	23/05/2012 17:13:12
Analysis Name	D:\Data\May 2012\116878_1-B,2_01_17208.d		
Method	steve200-2500lc.m		
Instrument	micrOTOF	Source Type	ESI
			Ion Polarity
			Positive
		Scan Begin	50 m/z
		Scan End	2500 m/z




Fig. (2): HRMS of **8b** using autosampler technique.

School of Chemistry Mass Spectrometry Service



Comment	EE-104	Operator	Tanya
Sample Name	116851	Acquisition Date	23/05/2012 16:43:39
Analysis Name	D:\Data\May 2012\116851_1-B,1_01_17207.d		
Method	steve200-2500lc.m		
Instrument	micrOTOF	Source Type	ESI
		Ion Polarity	Positive
		Scan Begin	50 m/z
		Scan End	2500 m/z




Fig. (3): HRMS of **8c** using autosampler technique.

School of Chemistry Mass Spectrometry Service



Comment	EE-176[36-45]	Operator	Tanya
Sample Name	116706	Acquisition Date	30/04/2012 16:38:05
Analysis Name	D:\Data\April 2012\116706_1-B,5_01_16985.d		
Method	steve200-2500lc.m		
Instrument	micrOTOF	Source Type	ESI
		Ion Polarity	Positive
		Scan Begin	50 m/z
		Scan End	2500 m/z




Fig. (4): HRMS of **8d** using autosampler technique.

School of Chemistry Mass Spectrometry Service

Comment	EE-175[32-35]	Operator	Tanya
Sample Name	116664	Acquisition Date	26/04/2012 11:01:50
Analysis Name	D:\Data\April 2012\116664_1-C,1_01_16940.d		
Method	steve200-2500lc.m		
Instrument	micrOTOF	Source Type	ESI
			Ion Polarity
			Positive
		Scan Begin	50 m/z
		Scan End	2500 m/z




Fig. (5): HRMS of **8e** using autosampler technique.

School of Chemistry Mass Spectrometry Service



Comment	EE-99	Operator	Tanya
Sample Name	EE-99	Acquisition Date	28/09/2011 12:01:18
Analysis Name	D:\Data\Sept.2011\EE-99.d		
Method	Anneke200-5000 syringe positive.m		
Instrument	micrOTOF	Source Type	ESI
			Ion Polarity
			Positive
		Scan Begin	200 m/z
		Scan End	5000 m/z




Fig. (6): HRMS of **8f** using syringe pump technique.

School of Chemistry Mass Spectrometry Service



Comment	EE-199[34-41]	Operator	Tanya
Sample Name	112950	Acquisition Date	25/01/2011 15:47:02
Analysis Name	D:\Data\January2011\112950_1-C,5_01_12309.d		
Method	steve 200-2500 lc.m		
Instrument	micrOTOF	Source Type	ESI
			Ion Polarity
			Positive
		Scan Begin	50 m/z
		Scan End	2500 m/z




Fig. (7): HRMS of **8f** using autosampler technique.

School of Chemistry Mass Spectrometry Service

Comment	EE-100	Operator	Tanya
Sample Name	EE-100	Acquisition Date	28/09/2011 11:18:48
Analysis Name	D:\Data\Sept.2011\EE-100.d		
Method	Anneke200-5000 syringe positive.m		
Instrument	micrOTOF	Source Type	ESI
			Ion Polarity
			Positive
		Scan Begin	200 m/z
		Scan End	5000 m/z




Fig. (8): HRMS of **8g** using syringe pump technique.

School of Chemistry Mass Spectrometry Service

Comment	EE-100[19-22]	Operator	Tanya
Sample Name	112951	Acquisition Date	25/01/2011 15:03:24
Analysis Name	D:\Data\Sept.2011\112951_1-C,4_01_12308.d		
Method	steve 200-2500 lc.m		
Instrument	micrOTOF	Source Type	ESI
			Ion Polarity
			Positive
		Scan Begin	50 m/z
		Scan End	2500 m/z




Fig. (9): HRMS of **8g** using autosampler technique.

School of Chemistry Mass Spectrometry Service



Comment	EE-93	Operator	Tanya
Sample Name	EE-93	Acquisition Date	28/09/2011 10:23:27
Analysis Name	D:\Data\Sept.2011\EE-93.d		
Method	Anneke200-5000 syringe positive.m		
Instrument	micrOTOF	Source Type	ESI
			Ion Polarity
			Positive
		Scan Begin	200 m/z
		Scan End	5000 m/z




Fig. (10): HRMS of **8h** using syringe pump technique.

School of Chemistry Mass Spectrometry Service



Comment	EE-95	Operator	Tanya
Sample Name	EE-95	Acquisition Date	28/09/2011 09:53:11
Analysis Name	D:\Data\Sept.2011\EE-95.d		
Method	Anneke200-5000 syringe positive.m		
Instrument	micrOTOF	Source Type	ESI
		Ion Polarity	Positive
		Scan Begin	200 m/z
		Scan End	5000 m/z




Fig. (11): HRMS of **8i** using syringe pump technique.



School of Chemistry Mass Spectrometry Service

Comment	EE-95	Operator	Tanya
Sample Name	112735	Acquisition Date	15/12/2010 09:42:35
Analysis Name	D:\Data\December2010\112735_1-A,7_01_12065.d		
Method	steve 200-2500 lc.m		
Instrument	micrOTOF	Source Type	ESI
		Ion Polarity	Positive
		Scan Begin	50 m/z
		Scan End	2500 m/z




Fig. (12): HRMS of **8i** using autosampler technique.